港股異動丨愛康醫療跌6.37% 大股東折價7.5%配股
格隆匯4月29日丨愛康醫療(01789.HK)跌6.37%,報21.3港元,總市值235.6億港元。愛康醫療公佈,獲控股股東喜馬拉亞有限公司知會,其於昨日與高盛(亞洲)訂立配售協議,以每股21.04港元向不少於六名獨立承配人配售3000萬股,較上日收市價22.75港元折讓7.5%,相當於已發行股本約2.7%。喜馬拉亞由為愛康主席李志疆及家族成員持有。根據聯交所最新權益披露資料顯示,2020年4月27日,愛康醫療遭執行董事兼財務總監趙曉紅在場內以每股均價22.3429萬港元減持200.3萬股,涉資4475.28萬港元。減持後,趙曉紅最新持股數目為13,012,000股,持股比例由1.36%降至1.18%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.